Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications. 2012

Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
Dipartimento di Scienze Mediche, Università del Piemonte Orientale A. Avogadro, Novara, Italy.

Inorganic nanosized drug carriers are a promising field in nanomedicine applied to cancer. Their conjugation with antibodies combines the properties of the nanoparticles themselves with the specific and selective recognition ability of the antibodies to antigens. Biomimetic carbonate-hydroxyapatite (HA) nanoparticles were synthesized and fully characterized; human IgGs, used as model antibodies, were coupled to these nanocrystals. The maximum loading amount, the interaction modelling, the preferential orientation and the secondary structure modifications were evaluated using theoretical models (Langmuir, Freundlich and Langmuir-Freundlich) spectroscopic (UV-Vis, Raman), calorimetric (TGA), and immunochemical techniques (ELISA, Western Blot). HA nanoparticles of about 30 nm adsorbed human IgGs, in a dose-dependent, saturable and stable manner with micromolar affinity and adsorption capability around 2.3 mg/m(2). Adsorption isotherm could be described by Langmuir-Freundlich model, and was due to both energetically homogeneous and heterogeneous binding sites on HA surface, mainly of electrostatic nature. Binding did not induce secondary structure modification of IgGs. A preferential IgG end-on orientation with the involvement of IgG Fc moiety in the adsorption seems most probable due to the steric hindrance of their Fab domains. Biomimetic HA nanocrystals are suitable substrates to produce nanoparticles which can be functionalized with antibodies for efficient targeted drug delivery to tumours.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000327 Adsorption The adhesion of gases, liquids, or dissolved solids onto a surface. It includes adsorptive phenomena of bacteria and viruses onto surfaces as well. ABSORPTION into the substance may follow but not necessarily. Adsorptions
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
January 2005, Krankenpflege Journal,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
January 1969, Pathologia et microbiologia,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
February 1976, European journal of biochemistry,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
May 2021, Advanced healthcare materials,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
January 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
June 1982, Infection and immunity,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
January 2021, Current medicinal chemistry,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
March 2010, Biomaterials,
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
December 1967, Science (New York, N.Y.),
Michele Iafisco, and Elena Varoni, and Michele Di Foggia, and Stefano Pietronave, and Milena Fini, and Norberto Roveri, and Lia Rimondini, and Maria Prat
July 1994, American journal of obstetrics and gynecology,
Copied contents to your clipboard!